Full Press Release Details
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025.
LXRX
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Key Takeaway: Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Price reaction · baseline $1.12 (2025-09-02 close) · hit after-hours · 2 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
-3.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus